Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iAdhere: adherence to weekly rifapentine + isoniazid for latent tuberculosis infection
2012-002094-58Phase 3Completed
- Sponsor
- Unidad de Investigación en Tuberculosis de Barcelona
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rifapentine and isoniazid in latent tuberculosis infection (LTBI) (3 arms), sponsored by Unidad de Investigación en Tuberculosis de Barcelona. Primary endpoint: Completion of therapy. Started Jun 2012; status: completed.
02
Drugs
rifapentineisoniazid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on 2012-002094-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002094-58.